The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AKERO THERAPEUTICS INC | COM | 00973Y108 | 78,498 | 3,150,019 | SH | SOLE | 3,150,019 | 0 | 0 | ||
APELLIS PHARMACEUTICALS INC | COM | 03753U106 | 16,382 | 501,584 | SH | SOLE | 501,584 | 0 | 0 | ||
PRECISION BIOSCIENCES INC | COM | 74019P108 | 23,254 | 2,791,578 | SH | SOLE | 2,791,578 | 0 | 0 | ||
VERONA PHARMA PLC | SPONSORED ADS | 925050106 | 2,138 | 456,770 | SH | SOLE | 456,770 | 0 | 0 |